Steven M Albelda
Overview
Explore the profile of Steven M Albelda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
189
Citations
14872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kimura K, Aicher A, Niemeyer E, Areesawangkit P, Tilsed C, Fong K, et al.
Vaccines (Basel)
. 2025 Feb;
13(2).
PMID: 40006725
In situ cancer vaccination is a therapeutic approach that involves stimulating the immune system in order to generate a polyclonal, anti-tumor response against an array of tumor neoantigens. Traditionally, in...
2.
Zhao Y, Moon E, Carpenito C, Paulos C, Liu X, Brennan A, et al.
Cancer Res
. 2024 Nov;
84(21):3702.
PMID: 39492678
No abstract available.
3.
Thompson J, Tilsed C, Davis C, Gupta A, Melidosian B, Sun C, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199568
Although immune checkpoint blockade (ICB) is currently approved for the treatment of extensive-stage small-cell lung cancer (SCLC) in combination with chemotherapy, relatively few patients have demonstrated durable clinical benefit (DCB)...
4.
Trivedi S, Tilsed C, Liousia M, Brody R, Rajasekaran K, Singhal S, et al.
Sci Rep
. 2024 May;
14(1):11006.
PMID: 38744944
With cancer immunotherapy and precision medicine dynamically evolving, there is greater need for pre-clinical models that can better replicate the intact tumor and its complex tumor microenvironment (TME). Precision-cut tumor...
5.
Noguera-Ortega E, Albelda S
Transl Lung Cancer Res
. 2024 May;
13(4):956-960.
PMID: 38736504
No abstract available.
6.
Thompson J, Li S, Jose J, Predina J, Gupta A, Eruslanov E, et al.
Am J Physiol Lung Cell Mol Physiol
. 2024 Mar;
326(5):L646-L650.
PMID: 38529551
Novel screening techniques for early detection of lung cancer are urgently needed. Profiling circulating tumor cell-free DNA (ctDNA) has emerged as a promising tool for biopsy-free tumor genotyping. However, both...
7.
Tilsed C, Sadiq B, Papp T, Areesawangkit P, Kimura K, Noguera-Ortega E, et al.
Proc Natl Acad Sci U S A
. 2024 Mar;
121(13):e2319856121.
PMID: 38513098
The use of lipid nanoparticles (LNP) to encapsulate and deliver mRNA has become an important therapeutic advance. In addition to vaccines, LNP-mRNA can be used in many other applications. For...
8.
Singhal S, Rao A, Stadanlick J, Bruns K, Sullivan N, Bermudez A, et al.
Cancer Res
. 2024 Jan;
84(7):1029-1047.
PMID: 38270915
Significance: The elucidation of the conditions and mechanisms by which human FcR+ myeloid effectors mediate cancer cell resistance and killing during antibody treatment could help develop improved strategies for treating...
9.
Lee I, Sharma N, Noguera-Ortega E, Liousia M, Baroja M, Etersque J, et al.
Mol Ther
. 2023 Nov;
31(12):3564-3578.
PMID: 37919903
Chimeric antigen receptor (CAR) T cell therapy has been successful for hematological malignancies. Still, a lack of efficacy and potential toxicities have slowed its application for other indications. Furthermore, CAR...
10.
Albelda S
Nat Rev Clin Oncol
. 2023 Oct;
21(1):47-66.
PMID: 37904019
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid tumours remains...